A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

被引：1
|
作者：
Richardson, Paul G. [1 ]
Jagannath, Sundar [2 ]
Moreau, Philippe [3 ]
Jakubowiak, Andrzej [4 ]
Raab, Marc S. [5 ,6 ]
Facon, Thierry [7 ]
Vij, Ravi [8 ]
White, Darrell J. [9 ]
Reece, Donna [10 ]
Benboubker, Lotfi [11 ]
Zonder, Jeffrey A. [12 ]
Deng, Wei [13 ]
Kroog, Glenn [14 ]
Singhal, Anil K. [13 ]
Lonial, Sagar [15 ]
机构：
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mt Sinai Med Ctr, New York, NY 10029 USA
[3] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France
[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[5] Heidelberg Univ, Med Ctr, Heidelberg, Germany
[6] German Canc Res Ctr, Heidelberg, Germany
[7] Hop Claude Huriez, Serv Malad Sang, Lille, France
[8] Washington Univ, Sch Med, St Louis, MO USA
[9] Queen Elizabeth 2 Hlth Sci Ctr, Div Hematol, Halifax, NS, Canada
[10] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[11] Hop Bretonneau, Ctr Reg Cancerol Henry Kaplan CHRU Tours, Serv Hematol & Therapies Cellulaires, Tours, France
[12] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[13] Abbott Biotherapeut Corp, Redwood City, CA USA
[14] Bristol Myers Squibb Co, Princeton, NJ USA
[15] Emory Univ, Div BMT, Winship Canc Inst Hematol & Med Oncol, Atlanta, GA 30322 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
202
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM).
    Jakubowiak, Andrzej
    Richardson, Paul
    Zimmerman, Todd M.
    Alsina, Melissa
    Kaufman, Jonathan L.
    Harvey, Colleen
    Brozo, Christine
    Kendall, Tara
    McAllister, Amanda
    Hideshima, Teru
    Sportelli, Peter
    Gardner, Lesa
    Anderson, Kenneth C.
    Giusti, Kathy
    BLOOD, 2008, 112 (11) : 1264 - 1265
  • [32] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study
    Siegel, D. S.
    Weber, D. M.
    Mitsiades, C. S.
    Dimopoulos, M. A.
    Harousseau, J. L.
    Rizvi, S.
    Howe, J.
    Reiser, D.
    Anderson, K. C.
    Richardson, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Siegel, David
    Weber, Donna
    Mitsiades, Constantine S.
    Rizvi, Syed
    Garcia-Vargas, Jose
    Howe, Jason
    Reiser, David
    Anderson, Kenneth C.
    Richardson, Paul
    BLOOD, 2008, 112 (11) : 1270 - 1270
  • [34] MM-011: A Phase 2 Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma in Japan
    Hagiwara, Shotaro
    Okamoto, Shinichiro
    Matsue, Kosei
    Iida, Shinsuke
    Sunami, Kazutaka
    Komeno, Takuya
    Suzuki, Kenshi
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Tobinai, Kensei
    Chou, Takaaki
    Kaneko, Hitomi
    Iwasaki, Hiromi
    Uemura, Chie
    Tamakoshi, Hiromi
    Zaki, Mohamed H.
    Doerr, Thomas
    Kuroda, Yoshiaki
    Ichinohe, Tatsuo
    BLOOD, 2015, 126 (23)
  • [35] Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)
    Derman, Ben A.
    Kubicki, Tadeusz
    Simmons, Heidi
    Afrough, Aimaz
    Zonder, Jeffrey A.
    Grinblatt, David L.
    Anderson, Larry D., Jr.
    Kin, Andrew
    Narula, Sunil
    Rayani, Shayan
    Gurbuxani, Sandeep
    Karrison, Theodore
    Jiang, Ken
    Major, Ajay
    Cooperrider, Jennifer H.
    Jacob, Allison P.
    Jakubowiak, Andrzej J.
    BLOOD, 2023, 142
  • [36] A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009).
    Jakubowiak, Andrzej J.
    White, Darrell
    Moreau, Philippe
    Facon, Thierry
    Vij, Ravi
    Kroog, Glenn Scott
    Kopit, Justin
    Singhal, Anil
    Palumbo, Antonio Pierangelo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023
    San Miguel, Jesus
    Mateos, Maria-Victoria
    Shah, Jatin J.
    Ocio, Enrique M.
    Rodriguez-Otero, Paula
    Reece, Donna
    Munshi, Nikhil C.
    Avigan, David
    Ge, Yang
    Balakumaran, Arun
    Marinello, Patricia
    Orlowski, Robert Z.
    Siegel, David
    BLOOD, 2015, 126 (23)
  • [38] A PHASE II SINGLE-ARM SAFETY STUDY OF ELOTUZUMAB IN COMBINATION WITH THALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
    Mateos, M. V.
    Granell, M.
    Oriol Rocafiguera, A.
    Martinez Lopez, J.
    Blade, J.
    Hernandez, M. T.
    Martin Sanchez, J.
    Gironella, M.
    Lynch, M.
    Bleickardt, E.
    Paliwal, P.
    Singhal, A.
    San Miguel, J.
    HAEMATOLOGICA, 2014, 99 : 361 - 362
  • [39] THE MM-021 CHINA REGISTRATION TRIAL: A PHASE 2 STUDY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN CHINESE RELAPSED/REFRACTORY MYELOMA PATIENTS
    Hou, J.
    Du, X.
    Jin, J.
    Cai, Z.
    Chen, F.
    Zhou, D.
    Yu, L.
    Ke, X.
    Li, X.
    Wu, D.
    Meng, F.
    Ai, H.
    Zhang, J.
    Chen, N.
    Mei, J.
    Wang, J.
    HAEMATOLOGICA, 2013, 98 : 341 - 341
  • [40] Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
    Dao-bin Zhou
    Li Yu
    Xin Du
    Jie Jin
    Zhen Cai
    Fangping Chen
    Xiaoyan Ke
    Xiao Li
    Depei Wu
    Fanyi Meng
    Huisheng Ai
    Jingshan Zhang
    Dena DeMarco
    Nianhang Chen
    Jay Mei
    Jianmin Wang
    Jian Hou
    International Journal of Hematology, 2015, 101 : 569 - 577
12345